Ebola Virus Shedding and Transmission: Review of Current Evidence

Journal of Infectious Diseases

Volumn 214, Issue , 2016, Pages S177-S184

  Vetter, Pauline ^a,b   Fischer, William A ^e   Schibler, Manuel ^a,b,c   Jacobs, Michael ^f   Bausch, Daniel G ^d   Kaiser, Laurent ^a,b,c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Laboratory of Virology and Swiss Reference Center for Emerging Viral Diseases   (Switzerland)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d TULANE UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Ebola virus; Shedding; Transmission

Indexed keywords

EBOLA VIRUS RNA; UNCLASSIFIED DRUG; VIRUS RNA;

AMNION FLUID; AQUEOUS HUMOR; ASYMPTOMATIC INFECTION; BLOOD ANALYSIS; BREAST MILK; CELL CULTURE; CEREBROSPINAL FLUID ANALYSIS; EBOLAVIRUS; FECES ANALYSIS; HEALTH CARE POLICY; HOSPITAL DISCHARGE; HUMAN; INFECTION RISK; LACRIMAL FLUID; PRIORITY JOURNAL; REVIEW; SALIVA ANALYSIS; SEMEN ANALYSIS; SEXUAL TRANSMISSION; SWEAT; URINALYSIS; VAGINA DISCHARGE; VIRUS ISOLATION; VIRUS SHEDDING; VIRUS TRANSMISSION; AFRICA; BODILY SECRETIONS; BODY FLUID; EPIDEMIC; FECES; FEMALE; GENETICS; HEMORRHAGIC FEVER, EBOLA; MALE; PHYSIOLOGY; TRANSMISSION; VIROLOGY;

AFRICA, WESTERN; BODILY SECRETIONS; BODY FLUIDS; DISEASE OUTBREAKS; EBOLAVIRUS; FECES; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; VIRUS SHEDDING;

EID: 84990960879     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw254     Document Type: Review

References (94)

1. Miranda ME, Miranda NL. Reston ebolavirus in humans and animals in the Philippines: a review. J Infect Dis 2011; 204(suppl 3):S757-60.
2. Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005; 438:575-6.
3. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377: 849-62.
4. Fletcher TE, Fowler RA, Beeching NJ. Understanding organ dysfunction in Ebola virus disease. Intensive Care Med 2014; 40:1936-9.
5. Fischer R, Judson S, Miazgowicz K, Bushmaker T, Prescott J, Munster VJ. Ebola virus stability on surfaces and in fluids in simulated outbreak environments. Emerg Infect Dis 2015; 21:1243-6.
6. Bibby K, Fischer RJ, Casson LW, Stachler E, Haas CN, Munster VJ. Persistence of Ebola virus in sterilized wastewater. Environ Sci Technol Lett 2015; 2:245-9.
7. Piercy TJ, Smither SJ, Steward JA, Eastaugh L, Lever MS. The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol. J Appl Microbiol 2010; 109:1531-9.
8. World Health Organization (WHO). Ebola response roadmap situation report. Geneva: WHO, 2016. http://apps.who.int/ebola/current-situation/ebola-situationreport-30-march-2016. Accessed 3 April 2016.
9. Ebola protection of health workers on the front line. Lancet 2014; 384:470.
10. Uyeki TM, Mehta AK, Davey RT Jr, et al. Clinical management of Ebola virus disease in the united states and europe. N Engl J Med 2016; 374:636-46.
11. Parra JM, Salmeron OJ, Velasco M. The first case of Ebola virus disease acquired outside Africa. N Engl J Med 2014; 371:2439-40.
12. Chevalier MS, Chung W, Smith J, et al. Ebola virus disease cluster in the United States-Dallas County, Texas, 2014. MMWR Morb Mortal Wkly Rep 2014; 63:1087-8.
13. Deen GF, Knust B, Broutet N, et al. Ebola RNA persistence in semen of Ebola virus disease survivors-preliminary report. N Engl J Med 2015; doi:10.1056/NEJMoa1511410.
14. Vetter P, Kaiser L, Schibler M, Ciglenecki I, Bausch DG. Sequelae of Ebola virus disease: the emergency within the emergency. Lancet Infect Dis 2016; 16:e82-91.
15. Christie A, Davies-Wayne GJ, Cordier-Lasalle T, et al. Possible sexual transmission of Ebola virus-Liberia, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:479-81.
16. Mate SE, Kugelman JR, Nyenswah TG, et al. Molecular evidence of sexual transmission of Ebola virus. N Engl J Med 2015; 373:2448-54.
17. Rodriguez LL, De Roo A, Guimard Y, et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179(suppl 1):S170-6.
18. Bausch DG, Towner JS, Dowell SF, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 2007; 196(suppl 2):S142-7.
19. Sagui E, Janvier F, Baize S, et al. Severe Ebola virus infection with encephalopathy: evidence for direct virus involvement. Clin Infect Dis 2015; 61:1627-8.
20. World Health Organization (WHO). Clinical care for survivors of Ebola virus disease. Geneva: WHO, 2016. http://apps.who.int/csr/resources/publications/ebola/guidance-survivors/en/index.html. Accessed 1 June 2016.
21. Calain P, Monroe MC, Nichol ST. Ebola virus defective interfering particles and persistent infection. Virology 1999; 262:114-28.
22. Akerlund E, Prescott J, Tampellini L. Shedding of Ebola virus in an asymptomatic pregnant woman. N Engl J Med 2015; 372:2467-9.
23. Schibler M, Vetter P, Cherpillod P, et al. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect Dis 2015; 15:1034-40.
24. de La Vega MA, Caleo G, Audet J, et al. Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J Clin Invest 2015; 125:4421-8.
25. Lanini S, Portella G, Vairo F, et al. Blood kinetics of Ebola virus in survivors and nonsurvivors. J Clin Invest 2015; 125:4692-8.
26. Towner JS, Rollin PE, Bausch DG, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 2004; 78:4330-41.
27. Prescott J, Bushmaker T, Fischer R, Miazgowicz K, Judson S, Munster VJ. Postmortem stability of Ebola virus. Emerg Infect Dis 2015; 21:856-9.
28. Thi EP, Mire CE, Lee AC, et al. Lipid nanoparticle siRNA treatment of Ebolavirus-Makona-infected nonhuman primates. Nature 2015; 521:362-5.
29. Marzi A, Feldmann F, Hanley PW, Scott DP, Gunther S, Feldmann H. Delayed disease progression in cynomolgus macaques infected with Ebola virus Makona strain. Emerg Infect Dis 2015; 21:1777-83.
30. Petrosillo N, Nicastri E, Lanini S, et al. Ebola virus disease complicated with viral interstitial pneumonia: a case report. BMC Infect Dis 2015; 15:432.
31. Kreuels B, Wichmann D, Emmerich P, et al. A case of severe Ebola virus infection complicated by gram-negative septicemia. N Engl J Med 2014; 371:2394-401.
32. Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 2015; 372:2423-7.
33. Mora-Rillo M, Arsuaga M, Ramirez-Olivencia G, et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med 2015; 3:554-62.
34. Howlett P, Brown C, Helderman T, et al. Ebola virus disease complicated by lateonset encephalitis and polyarthritis, Sierra Leone. Emerg Infect Dis 2016; 22:150-2.
35. Connor MJ Jr, Kraft C, Mehta AK, et al. Successful delivery of RRT in Ebola virus disease. J Am Soc Nephrol 2015; 26:31-7.
36. Fallah M. A cohort study of survivors of Ebola virus infection in Liberia (PREVAIL III) [abstract 74LB]. In: Program and abstracts of the 2016 Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 22-25 February 2016. http://www.croiconference.org/sessions/cohort-study-survivors-ebolavirus-infection-liberia-prevail-iii. Accessed 2 April 2016.
37. Sissoko D, Duraffour S, Kolie J, et al. Dynamics of Ebola virus clearance in semen in Guinea [abstract 75LB]. In: Program and abstracts of the Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 22-25 February 2016. http://www.croiconference.org/sessions/dynamics-ebola-virus-clearancesemen-guinea. Accessed 2 April 2016.
38. Sow MS, Etard JF, Baize S, et al. New evidence of Long-lasting persistence of Ebola virus genetic material in semen of survivors. J Infect Dis 2016; doi:10.1093/infdis/jiw078.
39. Arias A, Watson SJ, Asogun D, et al. Rapid outbreak sequencing of Ebola virus in SL identifies transmission chains linked to sporadic cases. Virus Evol 2016; doi:10.1093/ve/vew016.
40. Caluwaerts S, Fautsch T, Lagrou D, et al. Dilemmas in managing pregnant women with Ebola: 2 case reports. Clin Infect Dis 2016; 62:903-5.
41. Jacobs M, Rodger A, Bell DJ, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 2016; doi:10.1016/S0140-6736(16)30386-5.
42. Mitchell SW, McCormick JB. Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses. J Clin Microbiol 1984; 20:486-9.
43. Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol 2015; 235:153-74.
44. Leroy EM, Baize S, Volchkov VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000; 355:2210-5.
45. Alfson KJ, Avena LE, Beadles MW, et al. Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques. J Virol 2015; 89:6773-81.
46. WHO. Ebola haemorrhagic fever in Zaire, 1976. Report of an International Commission. Bull World Health Organ 1978; 56:271-93.
47. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999; 179(suppl 1):S87-91.
48. Khan AS, Tshioko FK, Heymann DL, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999; 179(suppl 1):S76-86.
49. Richards GA, Murphy S, Jobson R, et al. Unexpected Ebola virus in a tertiary setting: clinical and epidemiologic aspects. Crit Care Med 2000; 28:240-4.
50. Baron RC, McCormick JB, Zubeir OA. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ 1983; 61:997-1003.
51. Francesconi P, Yoti Z, Declich S, et al. Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerg Infect Dis 2003; 9:1430-7.
52. Dietz PM, Jambai A, Paweska JT, Yoti Z, Ksaizek TG. Epidemiology and risk factors for Ebola virus disease in Sierra Leone-23 May 2014 to 31 January 2015. Clin Infect Dis 2015; 61:1648-54.
53. Olu O, Kargbo B, Kamara S, et al. Epidemiology of Ebola virus disease transmission among health care workers in Sierra Leone, May to December 2014: a retrospective descriptive study. BMC Infect Dis 2015; 15:416.
54. Dean NE, Halloran ME, Yang Y, Longini IM. Transmissibility and pathogenicity of Ebola virus: a systematic review and meta-analysis of household secondary attack rate and asymptomatic infection. Clin Infect Dis 2016; 62:1277-86.
55. Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 2014; 371:2092-100.
56. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. Br Med J 1977; 2:541-4.
57. Promed. Ebola, lab accident death-Russia (Siberia). Archive no. 20040522.1377. Promed 22 May 2004.
58. Pokrovsky V, Allakhverdov A. Climate change: Russia prepares to ratify Kyoto. Science 2004; 304:1225.
59. Kortepeter MG, Martin JW, Rusnak JM, et al. Managing potential laboratory exposure to ebola virus by using a patient biocontainment care unit. Emerg Infect Dis 2008; 14:881-7.
60. Gunther S, Feldmann H, Geisbert TW, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011; 204(suppl 3):S785-90.
61. Lai L, Davey R, Beck A, et al. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA 2015; 313: 1249-55.
62. Cnops L, Gerard M, Vandenberg O, et al. Risk of misinterpretation of Ebola virus PCR results after rVSV ZEBOV-GP vaccination. Clin Infect Dis 2015; 60:1725-6.
63. Guimard Y, Bwaka MA, Colebunders R, et al. Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179(suppl 1):S268-73.
64. Jacobs M, Aarons E, Bhagani S, et al. Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. Lancet Infect Dis 2015; 15:1300-4.
65. Wong KK, Davey RT Jr, Hewlett AL, et al. Use of postexposure prophylaxis after occupational exposure to Zaire ebolavirus. Clin Infect Dis 2016; doi:10.1093/cid/ciw256.
66. WHO. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 1978; 56:247-70.
67. Dunn AC, Walker TA, Redd J, et al. Nosocomial transmission of Ebola virus disease on pediatric and maternity wards: Bombali and Tonkolili, Sierra Leone, 2014. Am J Infect Control 2016; 44:269-72.
68. Rowe AK, Bertolli J, Khan AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999; 179(suppl 1):S28-35.
69. Baggi FM, Taybi A, Kurth A, et al. Management of pregnant women infected with Ebola virus in a treatment centre in Guinea, June 2014. Euro Surveill 2014; 19: pii:20983.
70. Bower H, Grass JE, Veltus E, et al. Delivery of an Ebola virus-positive stillborn infant in a rural community health center, sierra leone, january 2015. Am J Trop Med Hyg 2015; 94:417-9.
71. Oduyebo T, Pineda D, Lamin M, Leung A, Corbett C, Jamieson DJ. A Pregnant patient with ebola virus disease. Obstet Gynecol 2015; 126:1273-5.
72. MoreauM, Spencer C, Gozalbes JG, et al. Lactatingmothers infected with Ebola virus: EBOV RT-PCR of blood only may be insufficient. Euro Surveill 2015; 20:pii:21017.
73. Bower H, Johnson S, Bangura MS, et al. Effects of mother's illness and breastfeeding on risk of Ebola virus disease in a cohort of very young children. PLoS Negl Trop Dis 2016; 10:e0004622.
74. World Health Organization (WHO). Ebola virus disease in pregnancy: screening and management of Ebola cases, contacts and survivors. Geneva: WHO, 2015. http://www.who.int/csr/resources/publications/ebola/pregnancy-guidance/en/. Accessed 18 September 2015.
75. Osterholm MT, Moore KA, Kelley NS, et al. Transmission of ebola viruses: what we know and what we do not know. MBio 2015; 6:e01154.
76. Judson S, Prescott J, Munster V. Understanding ebola virus transmission. Viruses 2015; 7:511-21.
77. Jaax N, Jahrling P, Geisbert T, et al. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory. Lancet 1995; 346:1669-71.
78. Jaax NK, Davis KJ, Geisbert TJ, et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996; 120:140-55.
79. Johnson E, Jaax N, White J, Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 1995; 76:227-36.
80. Wong G, Qiu X, Richardson JS, et al. Ebola virus transmission in guinea pigs. J Virol 2015; 89:1314-23.
81. Reed DS, Lackemeyer MG, Garza NL, Sullivan LJ, Nichols DK. Aerosol exposure to Zaire ebolavirus in three nonhuman primate species: differences in disease course and clinical pathology. Microbes Infect 2011; 13:930-6.
82. Kobinger GP, Leung A, Neufeld J, et al. Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J Infect Dis 2011; 204:200-8.
83. Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G, Kobinger G. Transmission of Ebola virus from pigs to non-human primates. Sci Rep 2012; 2:811.
84. Alimonti J, Leung A, Jones S, et al. Evaluation of transmission risks associated with in vivo replication of several high containment pathogens in a biosafety level 4 laboratory. Sci Rep 2014; 4:5824.
85. Twenhafel NA, Mattix ME, Johnson JC, et al. Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques. Vet Pathol 2013; 50:514-29.
86. Wamala JF, Lukwago L, Malimbo M, et al. Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007-2008. Emerg Infect Dis 2010; 16:1087-92.
87. Kerstiens B, Matthys F. Interventions to control virus transmission during an outbreak of Ebola hemorrhagic fever: experience from Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179(suppl 1):S263-7.
88. Sagripanti JL, Rom AM, Holland LE. Persistence in darkness of virulent alphaviruses, Ebola virus, and Lassa virus deposited on solid surfaces. Arch Virol 2010; 155:2035-9.
89. Sagripanti JL, Lytle CD. Sensitivity to ultraviolet radiation of Lassa, vaccinia, and Ebola viruses dried on surfaces. Arch Virol 2011; 156:489-94.
90. Sinclair R, Boone SA, Greenberg D, Keim P, Gerba CP. Persistence of category A select agents in the environment. Appl Environ Microbiol 2008; 74:555-63.
91. Westhoff Smith D, Hill-Batorski L, N'Jai A, et al. Ebola virus stability under hospital and environmental conditions. J Infect Dis 2016; 214(suppl 3):S142-4.
92. Bower H, Johnson S, Bangura MS, et al. Exposure-specific and age-specific attack rates for Ebola virus disease in Ebola-affected households, Sierra Leone. Emerg Infect Dis 2016; doi:10.3201/eid2208.160163.
93. Green E, Hunt L, Ross JC, et al. Viraemia and Ebola virus secretion in survivors of Ebola virus disease in Sierra Leone: a cross-sectional cohort study. Lancet Infect Dis 2016; doi:10.1016/S1473-3099(16)30060-3.
94. World Health Organization. Clinical management of patients with viral hemorrhagic fever. Geneva: World Health Organization, 2014.